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T he world of cellular and molecular immunology is exploding, as are the crea tive efforts of tumor immu-n ologists. The systematic molecular dissection of intracellular cell function and cell-cell interactions continues at a blinding pace. It is inconceivable that 
25 y ago, inuTIunologists identified T cells by watching for clump-
ing after mix ing with sheep red blood cells. These same scientists 
have evolved into today's new generation of immnnobiologists 
who categorize T cells by function, cytokine profile, and distribu-
tion. The helper and suppressor T cells of yesterday have been 
replaced with labels such as Th1, Th2, suppressor, cytolytic, cd{3, 
y/15, CD45RO+ (memory), and CLA+ (cutaneous lymphoid 
antigen). X - ray crystallographic evidence shows how the T -cell 
receptor docks with the major histocompatibility complex (MHC) 
mole cule to initiate an immulloregulatOll' response to a self or 
foreign antigen. "Knock out" mice have already confirmed the 
complex redundancy inherent in the immune response and have 
begun to answer the "what iPs ." Sorting t1u'ough this new w ealth 
of knowledge, immunobiologists have begun to devise clever nov el 
strategies aimed at battling that age-old enemy - cancer. 
Foremost in the development of all immunotherapy against any 
malignancy is the specific targeting of the tumor cells. Tlus raises 
several important issues . First, what are the tumor-specific antigens 
thac will serve as good targets? Second, how can the host-inunune 
system be made to recogluze these antigens? Third, what is the 
optimal immunotherapeutic intervention for inducing the desired 
immunologic anti-tumor response? 
Major developments in immunology, cell biology, and biochem-
istry during tl1e last decade have brought us significantly closer to 
aswering these questions. Even in the early 1980s, it was clear that 
MHC glycoproteins binding foreign antigens p layed an important 
role in the immune recognition of self lJersus non-self (Hammerling 
et ai, 1986). Therefore, the identifica tion of MHC class I-associated 
epitopes b ecame an essential task for the development of an 
anri-tumor immunotherapeutic strategy. In early studies, MHC 
class I-associated viral epitopes were correctly identified using 
functional studies. First, the most probable putative antigenic viral 
proteins were identified, and overlapping peptides were synthe-
sized. These peptides were then assayed, ill vitro, to determine 
whether they stimulated cytotoxic T cells isolated from infected 
mice. Although successful , tlus method was tedious, time-consum-
ing, and expensive. 
The seminal observation reported in 1991 by Falk el al that MHC 
class 1- associated peptides are restricted by allele-specific sequence 
motifs identified several important characteristics of MHC class I 
pep tides (Falk et ai, 1991). First, the majority of MHC class I 
epiropes are derived £i'om intracellular cytoplasmic proteins. Sec-
ond , MHC class I pep tides are res tricted in length from eight to ten 
amino acids, with the majority of alleles preferring nonamer and 
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decamer peptides. Tlurd, MHC class I pep tides are restricted in 
their sequence by an allele-specific sequence motif that iden tifies 
two or tlrree "anchoring" residues. These "anchors," detennined 
by MHC class I genotype, form the basis for the identification of 
putative T cell epitopes. For example, the murine MHC class I 
allele H-2Kb has anchoring residues at positions 5 and 8 and prefers 
octamer or noname.r peptides. Position 5 is restricted to an anllno 
acid with an aromatic side chain such as tyrosine (Y) or phenylal-
anine (F) , and position 8 is an aliphatic side chain anuno acid such 
as leucine (L), isoleucine (I) , valine (V), or methionine (M). T hus, 
most peptides bound to H - 2Kb have the generic sequence: 1-2-3-
4 - X- 6- 7 -X' (X = Y,F; X ' = L,r,V,M) (Falk ef ai, 1991; 
Rammensee et ai, 1995). This information facilitates the original 
approach of scal1lung a likely antigenic protein 's amino acid 
sequence for antigenic peptides, since most proteins w ill contain 
only a handful of motif-fitting eight- to ten-amino acid peptides . 
N aturally processed antigenic cytotoxic T cell viral epitopes tl1at do 
not conform to the sequence motif, however, have been identified 
(Rammensee et "I , 1995). In addition, it has been reported that 
70-80'10 of motif-based putative cytotoxic T cell epitopes contain-
ing one or two anchoring residues do not bind to the respective 
MHC class I molecules, and of the binding pep tides, only a 
minority are immunogenic (Feltkamp et ai, 1993) . The sequence 
1110 tif, therefore, serves as a guide that, when used properly, 
predicts tl1e putative immunogenic epitopes but does not supplant 
the actual identifica tion and characteriza tion of n aturally processed 
and presented MHC class I-associated antigens. 
Direct sequencing of MHC class r peptides becam e possible by 
the advent of technologic breaktluoughs in protein chenustry 
(tandem mass spectroscopy) and, in concert with the consensus 
motifs, allowed, for the first time, the identification , from smaller 
numbers of cells , large numbers of naturally processed and pre-
sented tumor epitopes (Hunt et ai , 1992). Using these m ethods, 
m any m elanoma-specific antigenic epitopes have been identified 
from patients and have becom e useful reagents in vaccination 
protocols (Cox e/ ai, 1994; Kawakami et ai, 1994; Rivoltini et ai, 
1995) . 
Addition al advances have identified many of the key players 
involved in the processing and presentatio n of cytoplasmic proteins 
for iml11unosurveillance at the cell surface. We now know that 
cytoplasmic proteins of self or foreign (viral, bacterial, parasitic, 
neoplastic) origin are proteolytically cleaved in tl1e cytosol by a 
protein complex called a proteasom e. T he peptides, ranging from 8 
to 25+ amino acids in length, ar e transported into t11e endoplasmic 
reticulum either via an ATP-dependent heterodimer unit called 
TAP (Transported associated with Antigen Processing) (Shepherd 
et ai, 1993 ) or heat shock protein chaperones (Srivas tava et ai, 
1994). In the endoplasmic reticulum, newly synthesized empty 
MHC class I a heavy chain-{32-microglobulin heterodim ers, stabi-
lized by calreticulin, bind appropriate motif-fitting peptides. Cal-
nexin , another chaperone protein, apparently stabilizes the newly 
formed trimel;c complex until it is transported via the Golgi 
complex to tl1e cell surface. In contrast, in the MHC class II 
p,lthway of antigen presentation, exogenous peptide is engulfed 
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in to an endocytic vesicle and is introduced to "empty" MHC class 
II molecules in an endosomalllysosomal compartment. Since cell 
membrane-associated proteins can be simultaneously engu lfed in to 
the endocytic vesicles, MHC class II heterodimers may present 
exogenous as well as endogenous antigens. O n the other hand, the 
MHC class [ pathway has never been shown to intersect the 
endosomal compartment, but naturally processed exogenous anti-
gens have been reported to be presented in the context of MHC 
class r glycoprote ins (Braciale and Braciale, 1991) . How th en does 
exogenous ly in trod uced antigen access MHC class I molecules? 
Tumor immunologists have chosen to tackle tlus question in 
several ways . One method takes advantage of the unjque gene 
defect in tile l~A-S cell line, which permits expression of 
"empty" fi ll able MHC class I molecules (Ljunggren and Kan'e, 
1985) . The parental RMA murine T lymphoma was chemically 
mutagenized, and selection for MHC class I-deficient cells pro-
du ced I~A-S. Beca use I~-S has a defect in the gene encoding 
for one of the TAP peptide transporter proteins, cytoso Lic peptides 
cannot be transported into the endoplasnuc reticulum (Attaya et nl, 
1992). T he "empty" MHC class I heterodimers are thermally labile, 
and at physiologic temperatures, "empty" mo lecules are denatured. 
After overnigh t incubation at subphysiologic temperatures (20°C-
31 °C), however, an abundan ce of cell surface "empty" MHC class 
I molecul es are detected and can be loaded with motif-conforming 
octam er or nonamer pep tides (Ljunggren et nl, 1990; Schumacher et 
nl, 1990; Fahnestock et nl, 1992). Using this approach, antigenic 
cytotoxic T cell epitopes have been loaded onto RMA-S to 
successfully induce immunoprotection in histocompatible mice 
(Carbone cl nl, 1988; De Bruijn et nl, 1991). 
Others have successfuJly stimulated T-cell responses by " bath-
ing" antigen-presenting cells in a concentrated sea of antigenic 
peptide. T hese studies suggested that other mechanisms for intro-
ducing exogenous antigen into the peptide-binding groove of 
MHC class I glycoproteins must exist. One possibility is that a 
hi gh-affinity peptide may be able to replace a lower affinity peptide 
presented at the cell surface (Pamer, 1994) . Another feasible 
explanation, i. e. that endocytosed exogenous peptides may gain 
entry in to the endoplasmic reticulum, has been extensively studjed 
and is believed not to occur. Professional antigen-presenting ceUs 
such as macrophages and dendritic cells, however, have been 
observed to stimulate naIve T cells to recognize exogenously added 
peptide antigen in the context of MHC class I (Rock et nl, 1993; 
Pamer, 1994). In addition , there is evidence that professional 
antigen-presenting cells and dendri tic ceUs in particular, may 
possess an alternate pathway for MHC class I antigen presentation, 
suggesting their vital role in the presentation of synthetic tumor 
antigens (Shennan el nl, 1992; Pfeifer ct til, 1993; Austyn, 1996). 
T he dendritic cell has long been suspected to be a central player 
in tile host response to foreign antigen. Several difFerent dendritic 
cells have been classified by their ol;gin into splenic dendritic cells, 
bone marrow-derived dendritic cells, and epidermal dendritic cells 
(Langerhan5 cells). T he question remains, however: are all den-
dritic cell s the same? Using both functional and developmental 
data, distinct populations derived from myefoid and lymphoid 
precursors have been identifIed (Romani and Schttler, 1992; Caux 
el nl, 1996). Dendritic cells derived from peripheral blood, spleen , 
and bone marrow have been shown to properly target exogenously 
pulsed peptide antigen for the induction of cytotoxic T-cell re-
sponses (Austyn, 1996) . One important reason for th eir potent 
immul1ostimula tory activity res ides in the expression of accessory 
co-stimulatory molecules such as B7-1 and B7-2, wluch are critical 
for the induction of a primary immune response. T cells stin1ULated 
by nonprofessional antigen-presenting cells (as occurs with vacci-
nation with free peptide) have been shown to become tolerant to 
the specific antigen (Aichele el ai, 1995). Next, dendritic cells are 
thought to act as the principal activators of resting, na'ive T cells and 
can efficiently transport antigens from the periphe,}' to lympho id 
organs . Furthermore, it has been theorized that the dendritic cell 
supports a "molecular dialogue" between dendritic cells, T cell.l, 
THE jOUllNAL OF INVESTIGATIV E DERMATOLOGY 
and B cells witlun the lymph node, thus coordinating the induction 
of an anti-tumor immune response. 
Thjs is particularly true of dendritic cell progenitors generated 
from bone marrow cultu res (Porgador and Gilboa, 1995; Paglia e/ 
nl, 1996) . Last year, Celluzzi elnl showed the potency of peptide-
pulsed bone marrow-derived dendrjtic cells in indu cing immuno-
protectio n using a murine m elanoma-based tumor m odel (Celluzzi 
ct nl, 1996) . Later , the seminal work by Zitvogel eL al demonstrated 
that bone marrow-derived dendritic cells were capable ofproperlr 
loading tumor-specific antigens after exposure to a mL"'(ture of 
MHC class I pep tides acid eluted from w hole tumor cells alld 
successfully inu11unoprotected the host animals against tumor chal-
lenge in iliree different murine tumor models (ZitvogeI et nl, 1996). 
These studies highlight the potency of bone marrow-derived 
dendritic cells, but more importantly, the potential utility of 
dendritic cell-based vaccines for the treatment of cancer patients 
w hose tumo rs express as yet unidentified antigens. 
This raises three important qucstions for tumor immunobiolo-
gists whose principal aim is to develop a practical and effective 
cellular vaccination protocol. First, what is the most potent 3ntigen-
presenting cell for inducin g an MHC class I-mediated immune 
response? Second, what is the optimal method of delivering antigen 
to the antigen-presenting cell? T lurd , w hat is tile most practical 
method for translating murine studies to human cllucal situations? 
T he first answer appears to be the bone marrow-derived den-
dritic cell. The second answer rema ins unknown, altl10ugh one 
novel promising possibility indirectly delivers antigen using a 
technologic marvel, the "gene g un. " A DNA construct encoding 
the target protein linked to a vira l promoter is coated onto gold 
beads, then irtiected epidermaUy or intradennally with the gene 
gun . T he DNA enters keratinocytes and fibroblasts, where the 
encoded protein products may be synthesized, and appropriate 
peptide antigens m ay be naturally processed and presented for 
recognition by circulating immune cell s (Pertmer et nl, 1995; Yallg 
and Sun, 1995; Haynes et nl, 1996). The epidermal location makes 
it ideal for inspection by Langerhans cells (epidermal dendritic 
cells) . Epidermal dendritic cells have been previously showl! ro 
stimulate primed anti-tumor cytotoxic T cells ;11 vitro (Romani and 
Schuler, 1992). In this issue of The J Ollnlnl, however, CeJluzzi el al 
(p. 716) show that epidermal dendritic cells can induce a primary 
antitumor cytotoxic T -cell response. T hey also show that epidermal 
dendritic cells can stimulate na'ive T cclls in a fashion comparable to 
bone marrow-derived dendritic cells, the most potent professional 
antigen-presenting cells. T hjs report, in cor~junction witll earlier 
work by the same labora tory (Condon et aI, 1996), provides a sound 
rationale for the development of an l;-tull1or immunization strafe-. 
gies that ta.rget antigen to epidermal dendritic cells ill 11;110 and 
welcomes in the new age of anti-tLU11or immunotherapy. 
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